近日，药明康德被国际知名评级机构Sustainalytics评为2023年“ESG（环境、社会及管治）行业最高评级”和“ESG区域（亚太）最高评级”企业。药明康德在责任公民、赋能客户、守护地球和社区共建四大ESG核心领域中取得了重大进展，获得了Sustainalytics的高度认可，位列全球医药同行排名前2%。
Sustainalytics是一家提供ESG研究、评级和数据的知名机构，为全球投资者制定和实施负责任的投资战略。Sustainalytics的ESG风险评级覆盖全球14,000多家公司，全面评估特定行业中企业所面临的重大ESG风险，并分析企业的风险管理能力。Sustainalytics充分肯定药明康德的风险管理体系和相关举措，在五个风险等级中将其评定为“低风险”。
作为负责任的企业公民，药明康德始终坚守可持续发展的核心经营理念，将ESG融入到公司战略和运营的方方面面。公司不断夯实风险管理体系，通过健全企业治理架构、深化合规文化、降低环境影响以及关注员工安全与福祉等举措，全面提升全球各运营基地的ESG管理水平，切实践行公司对于环境、社会及管治的承诺。
“感谢Sustainalytics将药明康德评定为‘ESG行业最高评级’和‘ESG区域（亚太）最高评级’企业，”药明康德副董事长兼ESG委员会主席胡正国先生表示。“我们将继续聚焦可持续发展战略，不断提升管理水平，积极履行企业社会责任，助力合作伙伴加速新药和突破性疗法的问世，造福全球病患。”
关于药明康德
药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。2022年，药明康德被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的5900多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。
了解更多药明康德的ESG信息，请访问：
https://esg.wuxiapptec.com/zh-cn
WuXi AppTec Recognized as a 2023 “ESG Industry Top Rated” and “ESG Regional (Asia/Pacific) Top Rated” Company by Sustainalytics
WuXi AppTec, a leading global provider of R D and manufacturing services that enables the global pharmaceutical and healthcare industry, was recently recognized by Sustainalytics as an “ESG Industry Top Rated” and “ESG Regional (Asia/Pacific) Top Rated” Company in 2023, placing it in the top 2% of the global pharmaceutical industry. This rating upgrade demonstrates WuXi AppTec’s progress across the Company’s four ESG pillars: being a responsible citizen, supporting our customers, protecting our planet and empowering our community.
Sustainalytics is a leading ESG research, ratings and data firm that supports investors around the world with the development and implementation of responsible investment strategies. Sustainalytics’ ESG Risk Ratings evaluate more than 14,000 global companies on their exposure to and management of industry-specific ESG risks. WuXi AppTec''s risk mitigation efforts in 2022 earned the Company a “low risk” rating and recognition as an ESG Top Rated Company from Sustainalytics.
As a responsible corporate citizen, WuXi AppTec remains committed to sustainable development and integrating ESG into every aspect of its business strategy and operations. To improve the ESG management capabilities of its sites around the world and deliver on its environmental, social and governance commitments, WuXi AppTec has continued to strengthen its risk management system, improve its corporate governance, further embed compliance into its culture, minimize its impact on the environment, and prioritize employees’ safety and well-being.
“We welcome Sustainalytics’ recognition of WuXi AppTec as an ‘ESG Industry Top Rated’ and ‘ESG Regional (Asia/Pacific) Top Rated’ Company,” said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee.“Our sustainability strategy will continue to guide us as we deliver on our commitments as a corporate citizen. We remain steadfast in our efforts to prioritize ESG initiatives while enabling our customers’ discovery, development and manufacturing of new medicines and groundbreaking therapies for patients worldwide.”
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 5,900 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
For more information on WuXi AppTec’s work in ESG , please visit:
https://esg.wuxiapptec.com/